NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

39.40USD
23 Jan 2015
Change (% chg)

$0.16 (+0.41%)
Prev Close
$39.24
Open
$39.04
Day's High
$40.30
Day's Low
$39.01
Volume
66,716
Avg. Vol
179,833
52-wk High
$53.47
52-wk Low
$17.34

NLNK.OQ

Chart for NLNK.OQ

About

NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians. Its HyperAcute cancer immunotherapies aim to treat non-small cell... (more)

Overall

Beta: --
Market Cap(Mil.): $1,101.61
Shares Outstanding(Mil.): 27.96
Dividend: --
Yield (%): --

Financials

  NLNK.OQ Industry Sector
P/E (TTM): -- 40.21 40.82
EPS (TTM): -1.17 -- --
ROI: -47.68 19.07 18.35
ROE: -54.43 19.85 19.25
Search Stocks

NewLink, GSK get U.S. funding for faster development of Ebola vaccines

- The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.

23 Dec 2014

NewLink, GSK get U.S. funding for faster development of Ebola vaccines

Dec 23 - The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.

23 Dec 2014

UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag

* Further funding of up to $90 mln to help vaccine roll-out (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)

11 Dec 2014

No serious side effects in Merck/Newlink Ebola vaccine test

LONDON - The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday.

02 Dec 2014

No serious side effects in Merck/Newlink Ebola vaccine test

LONDON, Dec 2 - The first people vaccinated with an experimental Ebola shot being developed by U.S. drugmaker Merck and Canada's NewLink have had no serious side effects so far but a few experienced mild fever, researchers said on Tuesday.

02 Dec 2014

Merck buys rights to NewLink's experimental Ebola vaccine

- Merck & Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine against the Ebola virus.

24 Nov 2014

UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine

(Adds terms of deal, details on WHO-coordinated trials; updates share movement)

24 Nov 2014

Merck buys rights to NewLink's experimental Ebola vaccine

Nov 24 - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.

24 Nov 2014

Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya

LONDON - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a program with funding from the Wellcome Trust.

29 Oct 2014

Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya

LONDON, Oct 29 - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a programme with funding from the Wellcome Trust.

29 Oct 2014

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,763 -21.00
Pfizer Inc. (PFE.N) $32.45 -0.36
Novartis AG (NOVN.VX) CHF85.50 +1.20
Merck & Co., Inc. (MRK.N) $62.49 -0.10
Roche Holding Ltd. (ROG.VX) CHF249.00 +7.00
Abbott Laboratories (ABT.N) $43.86 -0.63
Sanofi SA (SASY.PA) €83.58 +2.41
AstraZeneca plc (AZN.L) 4,733.50p +44.00
GlaxoSmithKline plc (GSK.L) 1,500.00p +11.50
Eli Lilly and Co (LLY.N) $72.13 -0.33

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Jefferson Research
$20.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks